Am­gen en­lists TCR start­up TScan to work on Crohn's in deal po­ten­tial­ly worth $500M+

Am­gen is tak­ing a clos­er look at us­ing T cells for in­flam­ma­tion, an­nounc­ing a new deal Tues­day with TCR up­start TScan Ther­a­peu­tics.

The com­pa­nies will team up to dis­cov­er new tar­gets for Crohn’s dis­ease, and Am­gen has the op­tion to ex­pand the agree­ment in­to ul­cer­a­tive col­i­tis. Am­gen is pay­ing $30 mil­lion up­front to use TScan’s plat­form for ex­am­in­ing how T cells in­ter­act with anti­gens in Crohn’s, and is promis­ing more than $500 mil­lion in biobucks as well as sin­gle-dig­it roy­al­ties.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER